"HIV Fusion Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS.
| Descriptor ID |
D023581
|
| MeSH Number(s) |
D27.505.519.957.500 D27.505.954.122.388.077.088.209 D27.505.954.122.388.538.500
|
| Concept/Terms |
HIV Fusion Inhibitors- HIV Fusion Inhibitors
- HIV Cell Fusion Inhibitors
- HIV Fusion Protein Inhibitors
- Fusion Inhibitors, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Fusion Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Fusion Inhibitors".
This graph shows the total number of publications written about "HIV Fusion Inhibitors" by people in this website by year, and whether "HIV Fusion Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Fusion Inhibitors" by people in Profiles.
-
Venanzi Rullo E, Ceccarelli M, Condorelli F, Facciol? A, Visalli G, D'Aleo F, Paolucci I, Cacopardo B, Pinzone MR, Di Rosa M, Nunnari G, Pellican? GF. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Mol Med Rep. 2019 Mar; 19(3):1987-1995.
-
Danial M, Root MJ, Klok HA. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors. Biomacromolecules. 2012 May 14; 13(5):1438-47.
-
Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, Lie YS, Whitby FG, Eckert DM, Hill CP, Root MJ, Kay MS. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol. 2010 Nov; 84(21):11235-44.
-
Kahle KM, Steger HK, Root MJ. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 2009 Nov; 5(11):e1000674.
-
Champagne K, Shishido A, Root MJ. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem. 2009 Feb 6; 284(6):3619-27.
-
Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J. 2007 Sep; 26(9):799-805.